Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(20%)
Results Posted
200%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Recruiting1
Enrolling by invitation1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

recruiting120%
enrolling_by_invitation120%
completed120%
terminated240%

Recent Activity

1 active trials
Showing 5 of 5
enrolling_by_invitationphase_2

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07734415
recruitingphase_2

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT07037901
completedphase_1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

NCT06060977
terminatedphase_1

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

NCT05984784
terminatedphase_1

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

NCT06304740

Clinical Trials (5)

Showing 5 of 5 trials
NCT07734415Phase 2

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

Enrolling By Invitation
NCT07037901Phase 2

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting
NCT06060977Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

Completed
NCT05984784Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Terminated
NCT06304740Phase 1

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5